Rabies Virus Presentation by Maliha Rashid
Rabies Virus Presentation by Maliha Rashid
Rabies Virus Presentation by Maliha Rashid
2
Rabies
• Rabies is a preventable viral illness spread by the
bite of a rabid animal.
3
Structure of Rabies Virus
4
Shape of Rabies Virus
5
Symbol Name Function
6
Properties
7
Classification
• Rabies viruses are divided into two types:
8
Replication Process- steps
1. Adsorption (receptors and virion interaction)
8.Assembly
10
Epidemiology
11
Pathogenesis
12
Clinical Manifestations
1. Incubation
2. Prodrome
3. acute neurologic period
4. coma
5. death (or, very rarely, recovery)
13
Host Defense Mechanisms
• Second, RABV can stimulate neurite development while also preventing cell
death. This permits virions to use the neurological system of the host as a mode of
transit to the brain.
14
Laboratory Techniques
1. Direct Microscopy: Histological i. Direct Rapid Immunohistochemical
Identification of Characteristic Cell Test (dRIT)
Lesions ii. Indirect Rapid Immunohistochemistry
2. Fluorescent Antibody Technique (FAT) Test (IRIT)
3. Rapid Rabies Enzyme iii. Immunochromatographic techniques
Immunodiagnosis (RREID) 7. Nucleic Acid Detection Techniques
4. Viral isolation
5. Demonstration of Antibodies
6. Newer Diagnostic Tests for Rabies
15
Conventional Diagnostic Tests for Rabies: Advantages and
Limitations
• Laboratory techniques in rabies were Luzzani in 1913 paved the way to
started as early as 1800 BC when for laboratory confirmation of rabies.
the first time Zinke demonstrated
that the infection could be • A definitive diagnosis of rabies can be
transmitted to a normal animal after made only with the appropriate
inoculating with saliva from a laboratory methods. The basic
rabid animal. techniques are described in the WHO
publication Laboratory Techniques
• The landmark discovery of Negri in Rabies and the OIE Manual of
bodies by Adelchi Negri in 1903 and Diagnostic Tests and Vaccines for
demonstration of their diagnostic Terrestrial Animals
significance by his wife Lina Negri-
16
Direct Microscopy:
Histological Identification of Characteristic
Cell Lesions
• Infected neuronal cells reveal aggregates the form of a rosette, within the
of viral particles “Negri bodies” which eosinophilic matrix.
are intracytoplasmic inclusion bodies
specific to rabies encephalitis,
demonstrated by histological tests Limitations
(Seller's Technique) on smears taken
from various areas of the brain. 1. Seller's method on unfixed tissue
smears has a very low sensitivity and
• Negri bodies vary in size from as small is only suitable for fresh specimens
as 3 μm to as large as 30 μm and are
generally circular or oval and deeply 2. time consuming, less sensitive, and
eosinophilic with characteristic more expensive
basophilic granules, often arranged in
17
Demonstration of Viral Agents
1. Fluorescent Antibody Technique (FAT)
The most widely used test for postmortem rabies diagnosis is WHO
and OIE.
18
FAT
• involves demonstration of the rabies virus nucleoprotein antigen (N) in
fresh brain smears of a suspected rabies case by using
immunofluorescence technique.
• It can also be used to confirm the presence of rabies antigen in cell
culture or in brain tissue of mice that have been inoculated for diagnosis.
• specificity and sensitivity = 99%
• Reliable results are obtained only when fresh brain tissue is used.
• Obtaining a postmortem brain biopsy/autopsy - challenge due to
religious, cultural values.
• FAT on corneal smears and nuchal skin biopsy
19
Rapid Rabies Enzyme Immunodiagnosis (RREID)
phase.
20
Continued…..
FAT.
22
Demonstration of Antibodies
• MNT, RFFIT, and FAVN have been described for this purpose
• The RFFIT is considered the gold standard assay and has been used to
estimate the titre of rabies virus neutralizing antibodies for several years.
23
Newer Diagnostic Tests for Rabies
24
Rabies Vaccine
In 1885, the first rabies vaccine was released, followed by a
better one in 1908. Vaccination against the virus has been
given to millions of individuals throughout the world. It is
listed as an essential medicine by the WHO
disease-prevention vaccine
25
• Rabies immunizations are safe for people of all
ages. A brief period of redness and soreness at the
injection site occurs in 35 to 45 percent of
persons, and 5 to 15% of people report fever,
headaches, or nausea.
26
o The vaccination is given in three doses over
the course of a month, on days zero, seven,
and either twenty-one or twenty-eight
o One research indicated that after 10 years,
97 percent of immunocompetent patients
had protective levels of neutralising
o Four doses over two weeks are suggested antibodies after receiving a booster dosage.
27
References
• Dreesen D. W. (1997). A global review of rabies vaccines for human use. Vaccine, 15 Suppl, S2–S6. https://
doi.org/10.1016/s0264-410x(96)00314-3
• Brunker, K., & Mollentze, N. (2018). Rabies Virus. Trends in microbiology, 26(10), 886–887. https://
doi.org/10.1016/j.tim.2018.07.001
• Fisher, C. R., Streicker, D. G., & Schnell, M. J. (2018). The spread and evolution of rabies virus: conquering new frontiers. Nature
reviews. Microbiology, 16(4), 241–255. https://doi.org/10.1038/nrmicro.2018.11
• Warrell, M. J., & Warrell, D. A. (2015). Rabies: the clinical features, management and prevention of the classic zoonosis. Clinical
medicine (London, England), 15(1), 78–81. https://doi.org/10.7861/clinmedicine.14-6-78
• Hemachudha, T., Ugolini, G., Wacharapluesadee, S., Sungkarat, W., Shuangshoti, S., & Laothamatas, J. (2013). Human rabies:
neuropathogenesis, diagnosis, and management. The Lancet. Neurology, 12(5), 498–513. https://
doi.org/10.1016/S1474-4422(13)70038-3
• Davis, B. M., Rall, G. F., & Schnell, M. J. (2015). Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to
Ask). Annual review of virology, 2(1), 451–471. https://doi.org/10.1146/annurev-virology-100114-055157
• Ahmad, T., Haroon, Khan, M., Murad, M. A., Baig, M., Murtaza, B. N., Khan, M. M., Harapan, H., & Hui, J. (2021). Research trends in
rabies vaccine in the last three decades: a bibliometric analysis of global perspective. Human vaccines &
immunotherapeutics, 17(9), 3169–3177. https://doi.org/10.1080/21645515.2021.1910000 28
THANKS
29